Roche reports Phase III METEOROID study results for MOGAD
The trial involved adults and adolescents aged 12 years and above with MOGAD, offering an open-label extension.
News
Atsena secures DMC approval for LIGHTHOUSE trial
Agenus announces Phase II results from gastroesophageal cancer therapy
First patient receives JANX014 dose in Janux’s trial for mCRPC
Precision receives CTA approval to expand ELIMINATE-B study
GlycoNex secures Japan’s PMDA approval for GNX1021 Phase I trial
Vir Biotechnology doses first patient in Phase I VIR-5500 trial
BioNTech and DualityBio report positive data for trastuzumab pamirtecan
